Eton reported Q3 2026 revenue of $57.9 million and raised full-year revenue guidance to more than $175 million while reporting progress across six pipeline programs.
Eton paid $10 million upfront for exclusive U.S. rights to the diazepam seizure-rescue film, with launch targeted for April 2027 pending final FDA approval.